Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment

Table 2

Small molecule/biological therapeutics targeting the Hedgehog pathway.

Molecule	Function	Phase/clinical trials	Cancer type	NCT Number
GDC-0449 (Vismodegib derivative)	SMO inhibitor	Phase 2	Basal cell carcinoma, ovarian cancer, metastatic pancreatic cancer, medulloblastoma, small cell lung cancer, metastatic prostate cancer, glioblastoma, and acute myeloid leukemia	NCT00833417; NCT01201915; NCT00739661; NCT01088815
Genistein	Downregulate Gli1	Phase 1/2	Colorectal cancer	NCT01985763
Sonidegib (LDE225)	SMO inhibitor	Phase 1/2	Prostate cancer, ovarian cancer, pancreatic cancer, and basal cell carcinoma	NCT02195973; NCT01487785; NCT01529450
5E1	Prevent HH ligand-Patched binding	Preclinical	Prostate cancer	N/A
Glasdegib (PF-04449913)	SMO inhibitor	Phase 1b/2	Acute myeloid leukemia, chronic myelomonocytic leukemia	NCT01841333; NCT01286467

The clinical trial information was accessed via https://clinicaltrials.gov with National Clinical TrialNumber (NCT Number).